Site Search
Professionals 188 results
Capabilities 60 results
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Industry
Practice Area
Privacy: Regulated Personal Information (RPI)
Winston’s Regulated Personal Information (RPI) Practice offers seamlessly integrated counseling and litigation services to companies looking for practical and solution-oriented assistance navigating the compliance, regulatory, and private class action enforcement risks presented by the emerging patchwork of complex (and often conflicting) privacy laws in the United States and beyond.
Experience 158 results
Experience
|April 2, 2026
Business Combination and Secured Financing of Keo World and Maha Capital AB
Served as legal counsel to KEO World, Inc., a Miami-based fintech platform specializing in embedded credit and B2B digital payments, in connection with its business combination with Maha Capital AB, a publicly listed investment company on Nasdaq Stockholm. The transaction, which closed on April 2, 2026, was structured as a reverse triangular merger through which KEO World became a wholly owned subsidiary of Maha, with KEO World's parent entity receiving approximately 141 million newly issued Maha shares and nearly 49.2 million earn-out warrants as consideration. In connection with the closing, Maha also executed two directed capital raises totaling USD 27 million at SEK 16 per share and announced a planned third raise of USD 8 million ahead of a contemplated dual listing on a U.S. national securities exchange. Based on publicly available disclosures, the combined transaction has been valued at approximately USD 680 million.
Experience
|March 18, 2026
Winston & Strawn LLP Advises Maxim Group LLC on $100 Million IPO of BHAV Acquisition Corp
Winston & Strawn LLP represented the underwriter, Maxim Group LLC, in connection with the $100 million initial public offering of BHAV Acquisition Corp. The offering consisted of 10,000,000 units priced at $10.00 per unit, with each unit comprising one Class A ordinary share and one right. Each right entitles the holder to receive one-fourth (1/4) of one Class A ordinary share upon the consummation of the Company’s initial business combination.
Experience
|March 16, 2026
Winston & Strawn LLP Paris advised La Phocéenne de Cosmétique in connection with the acquisition of Laboratoires de Biarritz.
Insights & News 1,482 results
Life at Winston
|April 22, 2026
|1 Min Read
Winston For Good Heroes: Martha Huffman is a Beneficent Beekeeper, Community Member & Colleague
Giving back to Fate, Texas—the small community where she has lived on her “ranchette” for the past 28 years—is a way of life for Martha. Beekeeping and local politics are simply the latest ways in which she pays her good fortune forward within Fate.
In the Media
|April 16, 2026
|4 Min Read
Winston Secures Transformative Antitrust Verdict for States in Live Nation and Ticketmaster Trial
A Winston & Strawn team, led by Jeffrey Kessler, secured an antitrust verdict on behalf of more than 30 states and the District of Columbia, with a Manhattan federal jury finding Live Nation Entertainment and Ticketmaster liable for violating federal and state antitrust laws in a decision that has the potential to transform the concert, music, and ticketing industry. The jury concluded that Ticketmaster unlawfully maintained a monopoly in the primary ticketing market for major concert venues and that Live Nation unlawfully monopolized the large amphitheater market, compelling artists to use its promotion services to access its venues. Jurors further found that this conduct resulted in higher ticket fees, leading to an approximate $1.72 overcharge per ticket for consumers.
In the Media
|April 10, 2026
|1 Min Read
Ben Smolij Discusses Shift in SEC Shareholder Proposal Process with Law.com
Winston & Strawn partner Ben Smolij was recently quoted in a Law.com article examining the U.S. Securities and Exchange Commission’s decision to no longer respond to most no-action requests under the Exchange Act Rule 14a-8, which permits qualifying shareholders to place proposals in a public company’s proxy materials, while allowing issuers to omit proposals that fall with the rule’s procedural or substantive exclusions. This announcement is a significant shift in the shareholder proposal process for the upcoming 2025-2026 proxy season.
Other Results 66 results
Law Glossary
Generic drugs are typically small, chemically synthesized molecules—that is, they have relatively low molecular weights, frequently less than 1000 daltons and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—a typical small molecule drug—has a molecular weight of 180 daltons.
Law Glossary
A biologic—or biologic product—is a medicine made from or by living cells, typically through a series of complex processing steps. The Public Health Service Act defines a “biological product” as “a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or another trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.” (42 U.S.C. § 262(i).)
Law Glossary
What Is a Qualified Retirement Plan?
A qualified retirement plan is a retirement plan established by an employer that is designed to provide retirement income to designated employees and their beneficiaries, which meets certain IRS Code requirements in terms of both form and operation. Common plan types are 401(k) plans, pension plans, and profit-sharing plans. A qualified retirement plan may allow for both employer and employee contributions. Employers must follow procedures to ensure participants and beneficiaries are able to receive their benefits. They must also stay apprised of changes in retirement plan laws and regulations. Qualified retirement plans provide certain tax advantages to employers and tax deferral advantages to employees who are contributing. Taxes on earnings from the contributions are also deferred until the employee withdraws them from the plan.